These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11504094)

  • 21. Varying relative biological effectiveness in proton therapy: knowledge gaps versus clinical significance.
    Grassberger C; Paganetti H
    Acta Oncol; 2017 Jun; 56(6):761-762. PubMed ID: 28464735
    [No Abstract]   [Full Text] [Related]  

  • 22. Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides.
    Sgouros G; Hobbs R; Josefsson A
    Curr Radiopharm; 2018; 11(3):209-214. PubMed ID: 29697036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles.
    Li H; Gu Y; Miki J; Hukku B; McLeod DG; Hei TK; Rhim JS
    Int J Oncol; 2007 Sep; 31(3):537-44. PubMed ID: 17671680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RBE and OER variations of mixtures of plutonium alpha particles and X-rays for damage to human kidney cells (T-1).
    Raju MR; Jett JH
    Radiat Res; 1974 Dec; 60(3):473-81. PubMed ID: 10881724
    [No Abstract]   [Full Text] [Related]  

  • 25. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A model for the relative biological effectiveness of protons: the tissue specific parameter α/β of photons is a predictor for the sensitivity to LET changes.
    Wedenberg M; Lind BK; Hårdemark B
    Acta Oncol; 2013 Apr; 52(3):580-8. PubMed ID: 22909391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation therapy of malignant disease.
    Wallner P
    J Am Osteopath Assoc; 1978 Apr; 77(8):606-21. PubMed ID: 348656
    [No Abstract]   [Full Text] [Related]  

  • 28. Cancer radioimmunotherapy with alpha-emitting nuclides.
    Couturier O; Supiot S; Degraef-Mougin M; Faivre-Chauvet A; Carlier T; Chatal JF; Davodeau F; Cherel M
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):601-14. PubMed ID: 15841373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calculations related to the possible use of photons, neutrons, negatively charged pions, protons, and alpha particles in radiotherapy.
    Alsmiller RG; Santoro RT; Armstrong TW; Barish J; Chandler KC; Chapman GT
    Radiat Res; 1974 Dec; 60(3):369-87. PubMed ID: 10881718
    [No Abstract]   [Full Text] [Related]  

  • 30. F(ab')2 fragments versus intact antibody--an isodose comparison.
    Humm JL; Chin LM; Macklis RM
    J Nucl Med; 1990 Jun; 31(6):1045-7. PubMed ID: 2189961
    [No Abstract]   [Full Text] [Related]  

  • 31. Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.
    Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Yamamoto W; Shuke N; Aburano T; Watanabe N; Takayama T; Michigishi T; Tonami N
    Jpn J Cancer Res; 1998 Aug; 89(8):870-8. PubMed ID: 9765625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons.
    Aghevlian S; Boyle AJ; Reilly RM
    Adv Drug Deliv Rev; 2017 Jan; 109():102-118. PubMed ID: 26705852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.
    Roselli M; Milenic DE; Brechbiel MW; Mirzadeh S; Pippin CG; Gansow OA; Colcher D; Schlom J
    Cancer Biother Radiopharm; 1999 Jun; 14(3):209-20. PubMed ID: 10850305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calculations of cellular microdosimetry parameters for alpha particles and electrons.
    Tung CJ; Liu CS; Wang JP; Chang SL
    Appl Radiat Isot; 2004 Nov; 61(5):739-43. PubMed ID: 15308137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative Biological Effectiveness Uncertainties and Implications for Beam Arrangements and Dose Constraints in Proton Therapy.
    Paganetti H; Giantsoudi D
    Semin Radiat Oncol; 2018 Jun; 28(3):256-263. PubMed ID: 29933885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanodosimetry and RBE values in radiotherapy.
    Lindborg L; Hultqvist M; Carlsson Tedgren Å; Nikjoo H
    Radiat Prot Dosimetry; 2015 Sep; 166(1-4):339-42. PubMed ID: 25953788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative evaluation of Ac225 vs Bi213 as therapeutic radioisotopes for targeted alpha therapy for cancer.
    Allen BJ
    Australas Phys Eng Sci Med; 2017 Jun; 40(2):369-376. PubMed ID: 28342027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The promise of targeted {alpha}-particle therapy.
    Mulford DA; Scheinberg DA; Jurcic JG
    J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted alpha therapy for cancer.
    Allen BJ; Raja C; Rizvi S; Li Y; Tsui W; Zhang D; Song E; Qu CF; Kearsley J; Graham P; Thompson J
    Phys Med Biol; 2004 Aug; 49(16):3703-12. PubMed ID: 15446799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The biological effectiveness of radon-progeny alpha particles. IV. Morphological transformation of Syrian hamster embryo cells at low doses.
    Martin SG; Miller RC; Geard CR; Hall EJ
    Radiat Res; 1995 Apr; 142(1):70-7. PubMed ID: 7899561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.